Contact Us |
H Jean Khoury,MD,Chair
The success of the Acute Leukemia Working Committee (ALWC) derives predominantly from a strong team with collaborative input. Committee leadership works closely with committee members, data managers, and transplant groups in the US and abroad. The ALWC is responsible for developing and promoting the scientific agenda, established with the input from WC members; determining priorities in the selection of high-impact studies; and ensuring timely progress in protocol development, statistical analyses, manuscript development, and publications. This committee strives to improve quality and efficiency and is guided by the three principles established by the CIBMTR Advisory Committee: publish peer-reviewed papers of high scientific impact, complete studies within a reasonable time period, and ensure inclusiveness and fairness within the study process.
The ALWC’s recent academic activity includes one presentation at the 2015 BMT Tandem Meetings, two presentations at the 2015 ASH Annual Meeting, and six submitted / accepted manuscripts. Nine proposals were selected for presentation to the ALWC at the 2015 BMT Tandem Meetings, and 27 proposals were submitted for the 2016 BMT Tandem Meetings. These numbers are a reflection of a rapidly evolving field and a high level of interest in the rich and vast data within the CIBMTR Research Database. We hope to continue to receive more great proposals from colleagues around the world!
Thanks to the significant number of lymphoma patients treated with HCT in the CIBMTR Research Database, the Lymphoma WC is able to provide information with the capacity to change clinical practice in many transplant-related issues. Current questions to be addressed within such a large registry are related to the role of HCT in rare types of lymphomas, comparative analyses between “experimental” stem cell sources and “more standard ones”, prognostic factors modifying the long-term outcome of HCT in different histologies and disease situations, and comparisons between allogeneic and autologous HCT in specific clinical scenarios. The Lymphoma WC is also in the position to be a major player in joint studies with other scientific transplant societies, such as the EBMT.
The Lymphoma WC has been extremely active over the last few years, in large part due to the extensive data available in the CIBMTR Research Database. The number of transplants for lymphoma added to the Research Database from 2000 through 2015 are listed in the table below. During the annual committee meeting at the 2014 and 2015 BMT Tandem Meetings, 12 and 8 new proposals were presented, respectively, and 3 were approved each year to be further developed and analyzed. The Lymphoma WC was also quite productive with presentations and publications in 2015. Committee investigators presented seven oral abstracts at national and international conferences, including two at the ASH Annual Meeting and three at the BMT Tandem Meetings. They published seven manuscripts in peer-reviewed journals, including one in Blood, three in Biology of Blood and Marrow Transplantation, and three in Bone Marrow Transplantation, giving an overall impact factor of 31.45.
CIBMTR research involves _______ major programs.
Click here to enter your answer. If you answer correctly, you will be entered into a drawing to win a CIBMTR prize!
The Recipient Data Management Team consists of 14 Clinical Research Coordinators, 5 located in Milwaukee and 9 located in Minneapolis. The Milwaukee team is led by Clinical Research Manager, Sharon Meiers, and the Minneapolis team is led by Clinical Research Recipient Data Management Supervisor, Kay Gardner.
Left to Right: Andrea Pope, Sharon Meiers, Amy Prentice, Tiffany Hunt, and Drea Benoit
Not featured: Kavita Bhavsar
Front Row (left to right): Peter Wallace, Andrea Mitsch, Alisha Mussetter, Liz Johnson
Back Row: Tina Thole, Elliott Mitchem, Christina Olson, Ally Draxler, Kristy Nutter, Kay Gardner
CRCs are also responsible for ad hoc projects related to other CIBMTR activities, including the Data Back to Centers application, BMT CTN, and Portal Help Desk. Two CRCs, Amy Prentice and Liz Johnson, have a different role; they work with CIBMTR IT to enhance FormsNet and improve data collection. All of the CRCs work on a variety of committees, across teams or within their own, to improve processes and better serve their customers.
The BMT CTN Steering Committee is currently under the leadership of Chair Steve Devine, MD (Ohio State University). Rick Jones, MD (Johns Hopkins) continues to serve as Vice-Chair, and Fred Appelbaum, MD (Fred Hutchinson Cancer Research Center) is now serving as Immediate Past-Chair.
Are you an investigator wanting to get involved? The CIBMTR and BMT CTN Orientation Session will be held Saturday, February 20, 7:00 – 8:00 am HAST, in room 323B. Presenters Marcelo Pasquini, MD, MS, and Bronwen Shaw, MD, PhD, will describe specific ways to participate in both programs.
Exhibit Hall 3
To get up-to-date information about BMT CTN studies, meetings, and news:
Each year, centers will have until March 1 to submit their consecutive HCT list to their CRC. Any discrepancies between the center’s list and the data reported in FormsNet, based on the audit process, will need to be resolved by June 30. If the discrepancies are not resolved, the center will be placed in “First Warning” for the CPI trimester ending August 31.
Outcomes reporting in allogeneic HCT is necessary to provide information requested by patients, insurers, and government agencies and to comply with current laws. The SCTOD contract requires the CIBMTR to conduct an analysis of one-year survival rates at each transplant center in the US annually. The report generated by the CIBMTR is meant to be useful as a quality improvement tool for transplant centers.
Summaries are created through a collaborative process involving CIBMTR Consumer Advocacy Committee members; CIBMTR and NMDP/Be The Match Medical Writers, Communications Specialists, and Patient Education Specialists; and CIBMTR Scientific Directors. Developing these summaries is one of the main initiatives of the Consumer Advocacy Committee.
The Consumer Advocacy Committee was created in 2005 as a subcommittee of the Advisory Committee to communicate CIBMTR research results and data to the non-medical community and to provide patient and donor perspectives during the development of the CIBMTR research agenda. Many members have personal experience as a donor, recipient, or family member.
Like us on Facebook and follow us on Twitter to stay up-to-date with important news and events. We promote our publications, share important content from other organizations, and advertise our key meetings and events. Join us today!
The Advisory Committee, made up of members from across the globe, maintains careful oversight of the CIBMTR research agenda. The committee members are listed on the CIBMTR website, and we sincerely thank all of our committee members for their time and efforts, particularly the following individuals who will complete their service in February.
The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement 5U24-CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-13-1-0039 and N00014-14-1-0028 from the Office of Naval Research; and grants from our corporate and private contributors, which are listed on the CIBMTR website.
Need an acronym defined? Review our list of common abbreviations.